Current Rheumatology Research

Cervical spine involvement frequently occurs in patients with Psoriatic Arthritis (PsA) even in absence of sacroiliitis. Long disease duration, high disease activity in the first five years and presence of peripheral involvement are all predictors of this peculiar articular involvement.

Scalp psoriasis, a skin condition characterized by red, thickened (erythematous), well-demarcated patches or plaques with overlying silvery-white scales, affecting part or all of the scalp, is an autoimmune disease accompanied by itchy skin. The disease is associated with faulty functioning of adaptive and innate components of immune systems. The key pro- inflammatory cytokines mediating immunopathology of psoriasis are IL-17 and IL-23 which promote proliferation of Th 17 cells which in turn induce proliferation of keratinocytes leading to the disease.

A key feature of chronic inflammatory disease is heterogeneity. For clinicians, this poses problems not only in disease diagnosis and assessment, but also in providing personalized disease management for the patients. There are at least two explanations for disease heterogeneity: First, different patient subgroups have different etiologies and subsequent pathways involvement, leading to a similar clinical outcome. Secondly, patients have similar etiologies but with different pathway modulations in patient subgroups, resulting in different degree of clinical outcome.

This study presents a comprehensive exploration into the shared molecular mechanisms linking psoriasis and major depressive disorder (MDD), two conditions that are increasingly recognized as having potential comorbidities. It offers new insights into the immune and genetic pathways that may contribute to both disorders, emphasizing the potential of CD19 as a biomarker and therapeutic target through the PPARγ/β-catenin/Wnt3a signaling pathway.

Psoriasis is primarily a chronic skin disease characterized by keratinocyte hyperplasia, as well as a systemic inflammatory disease associated with numerous comorbidities, including rheumatological psoriatic arthritis, cardiovascular and psychiatric complications. Approximately 2-3% of the global population is affected by psoriasis, and despite advances in the treatment, there are still limitations.